Viropil

Viropil Tablet

Composition (Per Tablet):

• Dolutegravir – 50 mg

• Lamivudine – 300 mg

• Tenofovir Disoproxil Fumarate – 300 mg

Product Description:

Viropil Tablet is a fixed-dose combination antiretroviral medication used for the treatment of HIV-1 infection in adults and adolescents. It contains Dolutegravir, Lamivudine, and Tenofovir Disoproxil Fumarate, three powerful agents that work synergistically to inhibit viral replication, strengthen the immune system, and help manage or delay the progression to AIDS (Acquired Immunodeficiency Syndrome).

Viropil is part of the first-line regimen recommended by international HIV treatment guidelines due to its high efficacy, good tolerability, and once-daily dosing.

Mechanism of Action:

• Dolutegravir is an integrase strand transfer inhibitor (INSTI) that blocks the integration of viral DNA into the host genome.

• Lamivudine and Tenofovir are nucleoside reverse transcriptase inhibitors (NRTIs), which interfere with the reverse transcription process essential for viral replication.

Together, these agents prevent the virus from multiplying and reduce the viral load in the bloodstream.

Indications:

• Treatment of HIV-1 infection in adults and adolescents aged ≥12 years weighing at least 40 kg

• Suitable for use in treatment-naïve and certain treatment-experienced patients

Key Features:

• Single-tablet regimen simplifies adherence

• Contains WHO-recommended first-line ART components

• Improves immune function (CD4 counts) and reduces viral load

• Reduces the risk of HIV-related complications and co-infections

• Supplied in tamper-proof, sealed HDPE bottles for safe global transit